机构

• 上海药物研究所 [19]
• 中国科学院大学 [1]

采集方式

• OAI收割 [19]
• iSwitch采集 [1]

内容类型

• 期刊论文 [20]

发表日期

• 2023 [2]
• 2022 [2]
• 2020 [1]
• 2019 [4]
• 2018 [3]
• 2017 [5]
• 更多

学科主题

筛选

浏览/检索结果: 共20条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 Design, Synthesis, and Pharmacological Evaluation of Isoindoline Analogues as New HPK1 Inhibitors 期刊论文  OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2023, 卷号: 66, 期号: 23, 页码: 16201-16221 作者:  Xie, Chenghu;  Liu, Bo;  Song, Zilan;  Yang, Ye;  Dai, Mengdi   |  收藏  |  浏览/下载：34/0  |  提交时间：2024/02/27 Degradation of Cyclin-Dependent Kinase 9/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs 期刊论文  OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2023, 页码: 17 作者:  Zeng, Yanping;  Xiao, Jian;  Xu, Yuanxin;  Wei, Fan;  Tian, Lina   |  收藏  |  浏览/下载：16/0  |  提交时间：2023/10/17 The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKK? and overcomes gefitinib resistance in non-small cell lung cancer 期刊论文  OAI收割 CANCER BIOLOGY & MEDICINE, 2022, 卷号: 19, 期号: 8, 页码: 1172-1192 作者:  He, Ting;  Gao, Yinglei;  Fang, Yanfen;  Zhang, Yangming;  Zhang, Shuwei   |  收藏  |  浏览/下载：26/0  |  提交时间：2024/03/21 HDAC inhibitor  c-Met  IKK?  NSCLC  gefitinib   F-18-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis 期刊论文  OAI收割 THERANOSTICS, 2022, 卷号: 12, 期号: 14, 页码: 6395-6408 作者:  Jiang, Yuchen;  Zeng, Qinghe;  Jiang, Qinghui;  Peng, Xia;  Gao, Jing   |  收藏  |  浏览/下载：42/0  |  提交时间：2022/12/13 F-18-FDG  FGFR  Therapeutic Response  PET/CT  mTOR/HK2   Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor-SN38 Conjugates for Targeted Drug Accumulation 期刊论文  OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2020, 卷号: 63, 期号: 10, 页码: 5421-5441 作者:  Zhu, Shulei;  Shen, Qianqian;  Gao, Yinglei;  Wang, Lei;  Fang, Yanfen   |  收藏  |  浏览/下载：19/0  |  提交时间：2020/12/24 Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure-activity relationship, crystal structural characterization and and in vivo study 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2019, 卷号: 9, 期号: 2, 页码: 351-368 作者:  Wei, Peng;  Liu, Bo;  Wang, Ruifeng;  Gao, Yinglei;  Li, Lanlan   |  收藏  |  浏览/下载：50/0  |  提交时间：2020/07/01 Fibroblast growth factor  Tyrosine kinase receptor  Structure-based  Crystallography  Selectivity  Hybrid  5-Hydrosulfonyl-5H- pyrrolo[2.3-b]pyrazine  Inhibitor   Simultaneous inhibition of PI3K alpha and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer 期刊论文  OAI收割 CANCER BIOLOGY & MEDICINE, 2019, 卷号: 16, 期号: 1, 页码: 66-+ 作者:     |  收藏  |  浏览/下载：26/0  |  提交时间：2020/07/01 PI3K alpha  CDK4/6  KRAS  NSCLC  CYH33   Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer 期刊论文  OAI收割 CANCER BIOLOGY & MEDICINE, 2019, 卷号: 16, 期号: 1, 页码: 66-83 作者:  Wang, Yuxiang;  Li, Xian;  Liu, Xueling;  Chen, Yi;  Yang, Chunhao   |  收藏  |  浏览/下载：20/0  |  提交时间：2024/03/21 PI3K alpha  CDK4/6  KRAS  NSCLC  CYH33   Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer 期刊论文  OAI收割 Cancer Biology and Medicine, 2019, 卷号: 16, 期号: 1, 页码: 66 作者:  Wang Yuxiang;  Li Xian;  Liu Xueling;  Chen Yi;  Yang Chunhao   |  收藏  |  浏览/下载：35/0  |  提交时间：2020/12/24 PI3Kα  CDK4/6  KRAS  NSCLC  CYH33   Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma 期刊论文  OAI收割 European journal of medicinal chemistry, 2018, 卷号: 163, 页码: 671-689 作者:  Wang, Qi;  Dai, Yang;  Ji, Yinchun;  Shi, Huanyu;  Guo, Zuhao   |  收藏  |  浏览/下载：113/0  |  提交时间：2019/01/08